Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after Treatment with Atorvastatin: The Randomized DIATOR Trial

BACKGROUND: Recent evidence suggests that the lipid-lowering agent atorvastatin is also a potent immunomodulator. The aim of this study was to investigate the possible effect of atorvastatin on the decline of residual beta cell function in recent-onset type 1 diabetes. METHODS AND FINDINGS: The rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Stephan, Herder, Christian, Schloot, Nanette C., Koenig, Wolfgang, Heise, Tim, Heinemann, Lutz, Kolb, Hubert
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055882/
https://www.ncbi.nlm.nih.gov/pubmed/21412424
http://dx.doi.org/10.1371/journal.pone.0017554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055882/
https://www.ncbi.nlm.nih.gov/pubmed/21412424
http://dx.doi.org/10.1371/journal.pone.0017554

Ejemplares similares